Antiviral therapies are notoriously difficult to develop, as viruses can quickly mutate to become resistant to drugs. But what if a new generation of antivirals ignores the fast-mutating proteins on the surface of viruses and instead disrupts their protective layers?
Medicare puts out new details for covering the Alzheimer’s drug Leqembi, as the health system readies for potential approval
WASHINGTON — The health care system is on the precipice of broad access to a treatment for Alzheimer’s for the first time — and it’s scrambling
June 22, 2023